Table 1.
Baseline Demographic and Plasma Redox Variables by Treatment Group
| Variable | All (n = 30)a |
Placebo (n = 10) |
Vitamin D (n = 20) |
P |
|---|---|---|---|---|
| Age (yr) | 63.5 ± 17.3 | 64.8 ± 17.5 | 64.0 ± 17.7 | 0.87 |
| Male | 6 (60) | 13 (65) | 0.78 | |
| African American | 12 (40) | 4 (40) | 10 (50) | 0.10 |
| BMI (kg/m2) | 30.6 ± 7.59 | 28.2 ± 9.9 | 31.5 ± 6.4 | 0.39 |
| APACHE II | 21 ± 9 | 23.2 ± 8.8 | 20 ± 9 | 0.37 |
| Infection on Admission | 13 (43) | 6 (60) | 7 (35) | 0.17 |
| Plasma 25(OH)D (ng/mL) | 21.4 ± 9.1 | 21.5 ± 12.2 | 21.1 ± 7.9 | 0.75 |
| 25(OH)D <20 ng/mL | 13 (43) | 5 (50) | 8 (40) | 0.59 |
| 25(OH)D <30 ng/mL | 25 (83) | 8 (80) | 17 (85) | 0.73 |
| Cys (μM) | 1.11 (0.60, 2.61) | 1.36 (0.69, 8.34) | 0.98 (0.57, 1.80) | 0.40 |
| CySS (μM) | 7.05 (4.60, 9.07) | 6.62 (4.26, 12.34) | 7.25 (4.24, 8.87) | 0.77 |
| %CySS | 83.42 (73.70, 93.20) | 82.32 (50.42, 94.03) | 85.74 (72.47, 90.16) | 0.88 |
| EhCySS (mV) | −51.16 ± 31.21 | −54.79 ± 46.39 | −49.34 ± 21.59 | 0.68 |
| GSH (μM) | 0.21 (0.07, 0.35) | 0.21 (0.08, 0.72) | 0.21 (0.07, 0.32) | 0.63 |
| GSSG (μM) | 0.04 (0.008, 0.24) | 0.04 (0.007, 0.22) | 0.09 (0.009, 0.30) | 0.46 |
| %GSSG | 34.18 (3.19, 66.05) | 11.53 (2.00, 59.90) | 40.31 (7.84, 67.63) | 0.37 |
| EhGSSG (mV) | −75.71 ± 40.94 | −88.20 ± 42.13 | −69.47 ± 40.05 | 0.27 |
Data reported as N (%), mean ± SD for normal distributions, or median (IQR) for non-normal distributions.
a
N = 27 for plasma redox outcomes (n = 9 for placebo group, n = 18 for vitamin D group).